NASDAQ:CPRX
Catalyst Pharmaceuticals Stock News
$15.06
-0.270 (-1.76%)
At Close: Jun 14, 2024
Investors Heavily Search Catalyst Pharmaceuticals, Inc. (CPRX): Here is What You Need to Know
02:00pm, Wednesday, 15'th Feb 2023 Zacks Investment Research
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors Heavily Search Catalyst Pharmaceuticals, Inc. (CPRX): Here is What You Need to Know
10:32am, Wednesday, 15'th Feb 2023
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA
12:20pm, Tuesday, 14'th Feb 2023 Zacks Investment Research
With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2
Catalyst Pharmaceutical (CPRX) Gains But Lags Market: What You Should Know
10:50pm, Monday, 13'th Feb 2023 Zacks Investment Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $15.54, moving +0.45% from the previous trading session.
Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why
05:45pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why
02:18pm, Wednesday, 08'th Feb 2023
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance
01:03pm, Tuesday, 07'th Feb 2023 GlobeNewswire Inc.
2022 Total Revenues Estimated at $214 Million, Representing 52% YoY Growth
5 Best High Earnings Yield Picks to Grow Your Wealth
12:45pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Stocks with high earnings yield have the potential to provide greater returns. PTEN, JBL, CPRX, AGCO and URBN are some stocks boasting high earnings yield to power your portfolio.
5 Best High Earnings Yield Picks to Grow Your Wealth
09:02am, Tuesday, 07'th Feb 2023
Stocks with high earnings yield have the potential to provide greater returns. PTEN, JBL, CPRX, AGCO and URBN are some stocks boasting high earnings yield to power your portfolio.
Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know
10:50pm, Monday, 06'th Feb 2023 Zacks Investment Research
Catalyst Pharmaceutical (CPRX) closed at $15.87 in the latest trading session, marking a -1.43% move from the prior day.
The 7 Best Growth Stocks to Buy for February 2023
05:14pm, Monday, 06'th Feb 2023
The search for growth stocks, or companies with high potential for future growth, is on. These growth stocks often represent young, rapidly-expanding companies that are reinvesting their earnings bac
Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock
02:00pm, Friday, 03'rd Feb 2023 Zacks Investment Research
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock
10:32am, Friday, 03'rd Feb 2023
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Catalyst Pharmaceuticals: Stable Upside Potential Amid Patent Infringement Concerns
01:54am, Wednesday, 01'st Feb 2023
Catalyst's rights acquisition of FYCOMPA is a significant step towards controlling the epilepsy treatment market share. The company's cash balance of $256 million is enough to fund its CapEx in 2023.
Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar?
11:20am, Tuesday, 31'st Jan 2023 Zacks Investment Research
Style Box ETF report for JPSE